IndiTreat®

People are different and so is their cancer, patients should be treated individually.

New The power of precision, For Every Oncologist, Today

At 2cureX, we’re pioneers of 3D microtumors in cancer therapy, focused on improving the outcomes of cancer treatment

Product launch

2cureX launches IndiTreat^® for metastasised colon cancer, the world’s first CE validated IVD based on microtumors

How IndiTreat works

How IndiTreat predicts tumor resistance and sensitivity

IndiTreat uses thousands of patient-derived microtumors to evaluate the response of your patients’ tumors to drugs and drug combinations. These include drugs recommended by guidelines and as a special request, we can test off label. We are able to recommend drugs as well as drug combinations. Drug combinations are of particular significance to IndiTreat, as IndiTreat is today the only practical means to test the effect of different combinations.

Measurement of drug resistance and sensitivity

Want to know more?

Want to know more?

Contact us

Please contact 2cureX for more information

Email: info@2cureX.com
Phone: +45 22115399
Web: www.IndiTreat.com

Upcoming events

January 21, 2021

Fight Cancer 2021, Redeye Event, Stockholm

Click here for more information

February 10, 2021

VATOR SWISS NORDIC BIO 2021 – The Annual Nordic Healthcare Investor Summit in Zürich

February 25, 2021

2cureX Year-End Report 2020

View previous reports

Key benefits of IndiTreat

Tumor resistance
Predict tumor resistance and sensitivity to cancer drugs
Right cancer treatment
Select the most appropriate treatment, in accordance with guidelines or off-label
Better patient outcome
Improve patient quality of life through in vitro testing of drug efficacy on the individual patient

2cureX - Product box

Help chemo-naïve CRC patients
Identify the most effective treatment in chemo-naïve colorectal cancer patients
Help late-stage CRC patients
Identify the most effective treatment in late-stage colorectal cancer patients
Functional precision medicine
Complement the genomic characterisation of tumours with functional data on resistance and sensitivity to drugs